Soligenix, Inc. (LON: 0A6I)
London
· Delayed Price · Currency is GBP · Price in USD
2.304
-0.026 (-1.10%)
At close: Jan 21, 2025
Soligenix Revenue
Soligenix had revenue of $364.18K USD in the twelve months ending September 30, 2024, down -62.09% year-over-year. In the year 2023, Soligenix had annual revenue of $839.36K, down -11.55%.
Revenue (ttm)
$364.18K
Revenue Growth
-62.09%
P/S Ratio
n/a
Revenue / Employee
$24.28K
Employees
15
Market Cap
5.01M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
Dec 31, 2019 | 4.63M | -611.53K | -11.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
Shell | 221.41B |
HSBC Holdings | 43.25B |
Unilever | 51.12B |
Rio Tinto Group | 42.87B |
RELX PLC | 9.30B |
BP p.l.c. | 144.69B |
British American Tobacco p.l.c. | 26.18B |
Soligenix News
- 5 weeks ago - Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 5 weeks ago - EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer - Benzinga
- 7 weeks ago - HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - PRNewsWire
- 2 months ago - Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 2 months ago - Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - PRNewsWire
- 2 months ago - Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - PRNewsWire
- 3 months ago - Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - PRNewsWire